CYAD-203 / Celyad Oncology - LARVOL DELTA

"Yeah, as it was fine not to mention CYAD-203 was discontinued (although preclinical). In short, in a short timeframe, the CMO, the CEO and CSO left..." (@BertrandBio)

Preclinical

Celyad Oncology Provides Outlook for 2022 (Businesswire) - "Enrollment continues in the KEYNOTE-B79 Phase 1b trial for CYAD-101. Preliminary data from the trial are expected in the second half of 2022; In addition, the KEYNOTE-B79 study will be the subject of a presentation at the upcoming American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium being held from January 20-22, 2022; Investigational New Drug (IND)-enabling studies continue for CYAD-203. Submission of the IND application for CYAD-203 is expected in the second half of 2022."

IND • P1 data • Trial status • Colorectal Cancer • Gastrointestinal Cancer • Oncology

Celyad Oncology to Present New Data on Allogeneic CAR T Therapy Program at the Society for Immunotherapy of Cancer Annual Meeting (Businesswire) - "Celyad Oncology SA...announced that three abstracts about the Company’s allogeneic CAR T therapy programs will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting taking place in Washington D.C. and virtually November 10-14, 2021. Posters will include additional information on Celyad’s multiplexing capabilities using short hairpin RNA (shRNA) technology, the Company’s first allogeneic, IL-18-armored CAR T candidate, CYAD-203, and the Phase 1b KEYNOTE-B79 trial of CYAD-101 in refractory metastatic colorectal cancer patients."

Clinical data • Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology

Celyad Oncology Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-based Preclinical Concepts at Research & Development Day (GlobeNewswire) - "Upcoming milestones: (i) Additional clinical activity data for the Phase 1 IMMUNICY-1 trial of CYAD-211 for r/r MM are expected during second half 2021; (ii) Study initiation for KEYNOTE-B79 Phase 1b is expected early fourth quarter 2021; (iii) Submission of an IND application for CYAD-203 is expected in mid-2022; (iv) Report additional data from the dose-escalation Phase 1 CYCLE-1 trial evaluating CYAD-02 in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome in mid-2021."

IND • New P1 trial • P1 data • Acute Myelogenous Leukemia • Colorectal Cancer • Gastrointestinal Cancer • Hematological Malignancies • Leukemia • Microsatellite Instability • Multiple Myeloma • Myelodysplastic Syndrome • Oncology